Edwards Lifesciences (NYSE:EW – Get Free Report) and Beta Bionics (NASDAQ:BBNX – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.
Risk and Volatility
Edwards Lifesciences has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.4, meaning that its share price is 240% more volatile than the S&P 500.
Institutional & Insider Ownership
79.5% of Edwards Lifesciences shares are owned by institutional investors. 0.3% of Edwards Lifesciences shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Edwards Lifesciences | 17.39% | 15.19% | 11.71% |
| Beta Bionics | -60.27% | -23.00% | -20.55% |
Earnings & Valuation
This table compares Edwards Lifesciences and Beta Bionics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Edwards Lifesciences | $6.07 billion | 8.50 | $1.07 billion | $1.88 | 47.64 |
| Beta Bionics | $100.25 million | 6.55 | -$73.20 million | ($1.51) | -9.75 |
Edwards Lifesciences has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and target prices for Edwards Lifesciences and Beta Bionics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Edwards Lifesciences | 0 | 8 | 16 | 3 | 2.81 |
| Beta Bionics | 1 | 3 | 6 | 1 | 2.64 |
Edwards Lifesciences presently has a consensus price target of $95.96, indicating a potential upside of 7.14%. Beta Bionics has a consensus price target of $19.70, indicating a potential upside of 33.74%. Given Beta Bionics’ higher probable upside, analysts clearly believe Beta Bionics is more favorable than Edwards Lifesciences.
Summary
Edwards Lifesciences beats Beta Bionics on 12 of the 15 factors compared between the two stocks.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
